89bio, Inc. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   Pegozafermin · MASH and Fibrosis (ENLIGHTEN-Fibrosis)

   Trial sites expanded: 367 → 370 locations

   89bio, Inc.·Phase 3· NCT06318169· Registry history of NCT06318169 on ClinicalTrials.gov (opens the registry)

   Oct 5, 2026

2. Minor

   Pegozafermin · Compensated Cirrhosis Due to MASH

   Trial sites expanded: 326 → 330 locations

   89bio, Inc.·Phase 3· NCT06419374· Registry history of NCT06419374 on ClinicalTrials.gov (opens the registry)

   Oct 5, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.